Stock Recap #PipelineProspector
Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn
The
raging war in the Middle East has disrupted global pharmaceutical supply
chains, which are dep
Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill
February
was a month of upheavals. In the US, the Supreme Court ruled that President Donald Trump
Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy
November saw several big ticket
acquisitions across the consumer health and biopharma space, includ
Pipeline Prospector September 2025: Genmab buys Merus for ~US$ 8 billion, Pfizer buys Metsera to enter obesity race
September saw a major clampdown on imports of “branded or patented drugs” into the US, t
Pipeline Prospector August 2025: Novo’s Wegovy approved for MASH, Tonix Pharma’s fibromyalgia drug okayed
In
August, the global pharmaceutical industry witnessed several regulatory
upheavals and policy sh
Pipeline Prospector July 2025: Merck to acquire Verona for US$ 10 bn; FDA okays Regeneron’s blood cancer med
In July, the pharmaceutical industry witnessed several deals and mergers and acquisitions (M&As). Bi
Pipeline Prospector June 2025: Sanofi, AbbVie, Eli Lilly, BioNTech lead pharma M&A spree; BMS, Astra ink major collaborations
In June, the pharmaceutical industry continued to witness more merger and acquisitions, deals, and g
Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking
In October, several pharma companies posted their third quarter (Q3) results. Drugmakers like Pfizer
Pipeline Prospector June 2024: FDA approves Merck’s next-gen pneumococcal vaccine, Verona’s COPD therapy
The pharma indices were back in the black in May, and the good streak continued through June with th
Pipeline Prospector April 2024: Indices dip amid muted Q1 results; Vertex acquires Alpine Immune for US$ 4.9 bn
Pharma indices had begun to recede in March. Their red streak accelerated in April with the Nasdaq B
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.